5-O-methylembelin: extracted from mangrove Aegiceras corniculatum; piscicide; see embelin [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
5-O-methyl embelin : A member of the class of monohydroxy-1,4-benzoquinones that is embelin in which the hydroxy group at position 5 is replaced by a methoxy group. Isolated from Lysimachia punctata and Embelia ribes, it exhibits antileishmanial activity as well as inhibitory activity towards hepatitis C protease. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|---|---|---|---|
| Ribes | genus | Also known as currant, ribes is a member of the family GROSSULARIACEAE. Oil extracted from the seeds contain GAMMA-LINOLENIC ACID.[MeSH] | Grossulariaceae | A plant family of the order ROSALES, subclass Rosidae, class Magnoliopsida. They are deciduous woody shrubs with alternate leaves. The flowers are in terminal racemes with 5 petals and 5 stamens.[MeSH] |
| Lysimachia | genus | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
| Aegiceras | genus | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
| Embelia ribes | species | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
| Lysimachia punctata | species | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
| ID Source | ID |
|---|---|
| PubMed CID | 171489 |
| CHEMBL ID | 471270 |
| CHEBI ID | 65842 |
| MeSH ID | M0169293 |
| Synonym |
|---|
| 5-o-methylembelin |
| 56005-10-8 |
| chebi:65842 , |
| CHEMBL471270 |
| 2-hydroxy-5-methoxy-3-undecylcyclohexa-2,5-diene-1,4-dione |
| 2-hydroxy-5-methoxy-3-undecyl[1,4]benzoquinone |
| unii-4h3r9623ba |
| 2,5-cyclohexadiene-1,4-dione, 2-hydroxy-5-methoxy-3-undecyl- |
| 2-hydroxy-5-methoxy-3-undecyl-1,4-benzoquinone |
| 4h3r9623ba , |
| 2-hydroxy-5-methoxy-3-undecyl-[1,4]benzoquinone |
| 5-o-methyl embelin |
| alpha-acetamido-2-methylcinnamicacid |
| DTXSID10204577 |
| bdbm50078845 |
| Q27134335 |
| 5-methoxy-2-oxidanyl-3-undecyl-cyclohexa-2,5-diene-1,4-dione |
| HY-W510159 |
| CS-0595743 |
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| hepatitis C protease inhibitor | An inhibitor of hepatitis C protease, an enzyme required for production of proteins needed for viral assembly. |
| antileishmanial agent | An antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania. |
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| enol ether | Ethers ROR' where R has a double bond adjacent to the oxygen of the ether linkage. |
| monohydroxy-1,4-benzoquinones | Any 1,4-benzoquinone carrying a single hydroxy substituent. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) | IC50 (µMol) | 1.9267 | 0.0001 | 1.6847 | 9.3200 | AID1201309; AID1201310; AID1201312 |
| Macrophage-expressed gene 1 protein | Homo sapiens (human) | IC50 (µMol) | 9.1000 | 0.2100 | 2.5240 | 9.1000 | AID1201316 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| arachidonate 5-lipoxygenase activity | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| arachidonate 12(S)-lipoxygenase activity | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| iron ion binding | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| protein binding | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| hydrolase activity | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| arachidonate 8(S)-lipoxygenase activity | Polyunsaturated fatty acid 5-lipoxygenase | Homo sapiens (human) |
| wide pore channel activity | Macrophage-expressed gene 1 protein | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1201312 | Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation in presence of arachidonic acid pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID1201310 | Inhibition of 5-LOX in A23187-stimulated human blood PMNL assessed as reduction in lipoxygenase products formation pre-incubated for 15 mins followed by stimulation with A23187 for 10 mins by RP-HPLC based cell based assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID1140543 | Inhibition of hexa-His-tagged PAI-1 N152H/K156T/Q321L/M356I mutant (unknown origin) expressed in Escherichia coli BL21(DE3) after 10 mins by uPA-based assay | 2014 | Bioorganic & medicinal chemistry letters, May-15, Volume: 24, Issue:10 | Design, synthesis, and SAR of embelin analogues as the inhibitors of PAI-1 (plasminogen activator inhibitor-1). |
| AID1201309 | Inhibition of human recombinant 5-LOX expressed in Escherichia coli BL21 incubated for 10 mins in presence of arachidonic acid by RP-HPLC based cell-free assay | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID1201317 | Inhibition of 15-LOX-1 in human blood PMNL assessed as remaining activity by measuring 15-HETE synthesis at 10 uM | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID1201316 | Inhibition of mPGES1 in IL-1beta stimulated human A549 cell microsomal membranes assessed as reduction in PGE2 synthase activity after 15 mins using PGH2 substrate by RP-HPLC method | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID1201319 | Inhibition of 12-LOX in human blood PMNL assessed as remaining activity by measuring 12-HETE synthesis at 10 uM | 2015 | European journal of medicinal chemistry, Apr-13, Volume: 94 | Novel series of benzoquinones with high potency against 5-lipoxygenase in human polymorphonuclear leukocytes. |
| AID401550 | Cytotoxicity against human HeLa cells after 48 hrs by MTT assay | 2004 | Journal of natural products, May, Volume: 67, Issue:5 | Chemical constituents from the mangrove plant, Aegiceras corniculatum. |
| AID401549 | Cytotoxicity against human Bel7402 cells after 48 hrs by MTT assay | 2004 | Journal of natural products, May, Volume: 67, Issue:5 | Chemical constituents from the mangrove plant, Aegiceras corniculatum. |
| AID355619 | Antifungal activity against Pythium ultimum at 1 mg | |||
| AID401551 | Cytotoxicity against human U937 cells after 48 hrs by MTT assay | 2004 | Journal of natural products, May, Volume: 67, Issue:5 | Chemical constituents from the mangrove plant, Aegiceras corniculatum. |
| AID355618 | Toxicity in Tilapia nilotica at 1 ppm within 75 mins | |||
| AID401548 | Cytotoxicity against human HL60 cells after 48 hrs by MTT assay | 2004 | Journal of natural products, May, Volume: 67, Issue:5 | Chemical constituents from the mangrove plant, Aegiceras corniculatum. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.13) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||